On July 22, 2019 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body’s immune system to fight cancer, reported that it is partnering with the VA Maryland Health Care System’s Baltimore VA Medical Center and the Baltimore Research and Education Foundation, a non-profit affiliate, in its ongoing prostate cancer Cchek study (Press release, Anixa Biosciences, JUL 22, 2019, View Source [SID1234537644]). Led by Dr. Minhaj Siddiqui, chief of Urology at the VA Maryland Health Care System and Associate Professor and Director of Urologic Oncology and Robotic Surgery at the University of Maryland School of Medicine, study enrollment is expected to begin in August of this year and will include men who are at risk for prostate cancer in a yearlong study that seeks to advance the Check liquid biopsy for prostate cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to be working with Dr. Siddiqui and the VA Maryland Health Care System as we continue development of our artificial intelligence based prostate cancer liquid biopsy," stated Dr. Amit Kumar, President and CEO of Anixa.